Page 20 - Read Online
P. 20

Braun. J Transl Genet Genom. 2025;9:35-47  https://dx.doi.org/10.20517/jtgg.2024.79  Page 45

               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2025.


               REFERENCES
               1.       Salari N, Fatahi B, Valipour E, et al. Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-
                   analysis. J Orthop Surg Res. 2022;17:96.  DOI  PubMed  PMC
               2.       Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7:13.  DOI
                   PubMed  PMC
               3.       Mercuri E, Bönnemann CG, Muntoni F. Muscular dystrophies. Lancet. 2019;394:2025-38.  DOI  PubMed
               4.       Pane M, Mazzone ES, Sormani MP, et al. 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes.
                   PLoS One. 2014;9:e83400.  DOI  PubMed  PMC
               5.       McDonald CM, Henricson EK, Abresch RT, et al; PTC124-GD-007-DMD Study Group. The 6-minute walk test and other clinical
                   endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a
                   multicenter study. Muscle Nerve. 2013;48:357-68.  DOI
               6.       Topaloglu H. Duchenne muscular dystophy: a short review and treatment update. Iran J Child Neurol. 2021;15:9-15.  DOI
               7.       Elangkovan N, Dickson G. Gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8:S303-16.  DOI  PubMed
                   PMC
               8.       Mozin E, Massouridès E, Mournetas V, et al. Dystrophin deficiency impairs cell junction formation during embryonic myogenesis.
                   bioRxiv. 2024.  DOI  PubMed  PMC
               9.       Sohn J, Lu A, Tang Y, Wang B, Huard J. Activation of non-myogenic mesenchymal stem cells during the disease progression in
                   dystrophic dystrophin/utrophin knockout mice. Hum Mol Genet. 2015;24:3814-29.  DOI  PubMed  PMC
               10.      Bostick B, Ghosh A, Yue Y, Long C, Duan D. Systemic AAV-9 transduction in mice is influenced by animal age but not by the route
                   of administration. Gene Ther. 2007;14:1605-9.  DOI
               11.      Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne’s muscular dystrophy. N Engl J Med.
                   2010;363:1429-37.  DOI
               12.      Bönnemann CG, Belluscio BA, Braun S, Morris C, Singh T, Muntoni F. Dystrophin immunity after gene therapy for Duchenne’s
                   muscular dystrophy. N Engl J Med. 2023;388:2294-6.  DOI  PubMed
               13.      Bladen CL, Salgado D, Monges S, et al. The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular
                   dystrophy mutations. Hum Mutat. 2015;36:395-402.  DOI
               14.      Sun C, Shen L, Zhang Z, Xie X. Therapeutic strategies for Duchenne muscular dystrophy: an update. Genes. 2020;11:837.  DOI
                   PubMed  PMC
               15.     Duan D, Goemans N, Takeda S. et al. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7:13.  DOI  PubMed  PMC
               16.      EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine translarna. Available from: https://www.
                   ema.europa.eu/en/news/ema-recommends-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine-translarna-0 [Last
                   accessed on 24 Jan 2025].
               17.      Brun C, Suter D, Pauli C, et al. U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping. Cell Mol Life Sci.
                   2003;60:557-66.  DOI  PubMed  PMC
               18.      Takeda S, Clemens PR, Hoffman EP. Exon-skipping in Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8:S343-58.  DOI
                   PubMed  PMC
               19.      Leckie J, Zia A, Yokota T. An updated analysis of exon-skipping applicability for Duchenne muscular dystrophy using the UMD-
                   DMD database. Genes. 2024;15:1489.  DOI  PubMed  PMC
               20.      Neri M, Torelli S, Brown S, et al. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human.
                   Neuromuscul Disord. 2007;17:913-8.  DOI
               21.      Wells DJ. What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy? J Muscle Res
                   Cell Motil. 2019;40:141-50.  DOI
               22.      Relizani K, Echevarría L, Zarrouki F, et al. Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching
                   oligonucleotides. Nucleic Acids Res. 2022;50:17-34.  DOI  PubMed  PMC
               23.      Cochran M, Marks I, Albin T, et al. Structure-activity relationship of antibody-oligonucleotide conjugates: evaluating bioconjugation
                   strategies for antibody-phosphorodiamidate morpholino oligomer conjugates for drug development. J Med Chem. 2024;67:14868-84.
                   DOI
               24.      Gushchina LV, Bradley AJ, Vetter TA, et al. Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-
                   mediated therapy in the Dup2 mouse model. Mol Ther Methods Clin Dev. 2023;31:101144.  DOI
               25.      Muntoni F, Signorovitch J, Sajeev G, et al; Association Française Contre Les Myopathies; on behalf of Universitaire Ziekenhuizen
                   Leuven Group; PRO-DMD-01; The UK NorthStar Clinical Network; CCHMC; and The DMD Italian Group. DMD genotypes and
   15   16   17   18   19   20   21   22   23   24   25